News about Global Pharma

Azenta Receives Regulatory Approval for Clinical Long-Read WGS Test

Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory, the test enables precise detection of a range of complex genomic alterations that are features of many rare diseases and undetectable by traditional approaches.

Global Pharma | 15/11/2024 | By Aishwarya |  364

Flare Therapeutics Partners with Roche Accelerate Drug Discovery in Oncology

This partnership will leverage Flare Therapeutics' proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecule drugs aimed at previously undrugged transcription factor targets in oncology.

Global Pharma | 14/11/2024 | By Aishwarya |  711

AstraZeneca Announces Investment of USD 3.5 Billion in R&D in US

AstraZeneca’s expanding footprint in the US includes, a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts, a next generation manufacturing facility for biologics in Maryland, cell therapy manufacturing capacity on the West and East Coasts and a specialty manufacturing in Texas.

Global Pharma | 14/11/2024 | By Aishwarya |  377

Vaxinano Signs Exclusive Licensing Deal for Canine Leishmaniasis Vaccine with Vetoquinol

Canine leishmaniasis is an incurable multisystemic zoonosis caused by a parasite that leads to death in symptomatic dogs, affecting globally 100 million dogs.

Global Pharma | 13/11/2024 | By Aishwarya |  730

Alembic Pharmaceuticals Bags USFDA Final Approval for Diltiazem Hydrochloride Capsules

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Cardizem CD Extended-Release Capsules, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, of Bausch Health US, LLC.

Global Pharma | 12/11/2024 | By Aishwarya |  604

Lakeside Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical

The acquisition, valued at RMB 4.0 million (USD 0.6 million), is anticipated to deliver approximately USD 7 million of annual revenues to Lakeside.

Global Pharma | 12/11/2024 | By Aishwarya |  251

Alteogen Signs Exclusive License Deal with Daiichi Sankyo to Develop Subcutaneous ENHERTU

Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme Technology, to develop and commercialize a subcutaneous version of ENHERTU (fam-trastuzumab deruxtecan-nxki).

Global Pharma | 11/11/2024 | By Aishwarya |  545

Union Minister for Chemicals and Fertilizers Unveils Scheme for Strengthening Medical Device Industry

The scheme is a comprehensive scheme which targets critical areas of the medical device industry, covering manufacturing of key components and accessories, skill development, support for clinical studies, development of common infrastructure and industry promotion.

Global Pharma | 11/11/2024 | By Aishwarya |  283

Samsung Biologics Secures ISO Certifications for its Business Excellence

The certifications were presented by the British Standards Institution (BSI) during a ceremony held at Samsung Biologics' headquarters.

Global Pharma | 11/11/2024 | By Aishwarya |  672

Parallel Fluidics Secures USD 7 Million Seed Round to Boost Microfluidic Development

The funding will help drive the growth of the company's on-demand design and manufacturing platform, expand its hardware and software solutions, and commercialize its new product, MV-2.

Global Pharma | 08/11/2024 | By Aishwarya |  407